BioLinker
PrivateLast Round
Seed
Oct 6, 2026
Est. Valuation
$12.92M
Total Funding Raised
$190,000
Momentum
Top 5%
of companies Caplight tracks
Company Overview
BioLinker is a biotechnology company that provides synthetic biology solutions, including cell-free protein expression kits and custom protein synthesis services for research and industrial applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioLinker Comparables
Compare BioLinker with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tierra Biosciences | 81% | |
| Liberum Biotech | 80% | |
| Synthelis Biotech | 79% |
BioLinker Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 6, 2026 | ||||
| Angel | Jun 22, 2022 | ||||
| Grant | Feb 4, 2021 |
BioLinker Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Financiadora de Estudos e Projetos | Grant |
| Cietec | Accelerator |
| Axcell Aceleradora | Seed |
| FAPESP | Grant, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 6, 2026
$1.7M raised with FAPESP participating.
- Jul 26, 2026
Monthly visitors increased 44% MoM.
Recent news
Latest coverage and updates
- expands_offices_toOct 9, 2026
Biolinker raises R$ 7.3 million to open a branch in Manaus, expanding its production capacity for on-demand proteins, on Oct 9th '26.
- expands_facilitiesOct 6, 2026
Biolinker plans to use $1.7M in funding to build an automated laboratory at the Amazon BioBusiness Center in Brazil, using robotics to generate biological data at scale and expand DNA production.
- receives_financingOct 6, 2026
Biolinker receives $1.69M in a new investment round, including R$7.2M from Axcell and funding from FAPESP’s PIPE Phase 2 program, to finance an automated laboratory, expand DNA production, and train AI in Amazonas on Oct 6th '26.
- receives_financingOct 6, 2026
On Oct 6th '26, Biolinker received a $1.4M investment from Axcell to open a new laboratory and expand production capacity in Brazil.
BioLinker Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BioLinker's valuation, stock price, and market status.
Is BioLinker a public or private company?
BioLinker is a private company.
What is the current stock price of BioLinker?
BioLinker is a private company, so its shares have no public market price. Caplight tracks BioLinker's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioLinker worth (valuation)?
BioLinker's valuation is estimated at $12.9M based on funding round data.
Can I buy BioLinker stock?
BioLinker shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioLinker's last funding round?
BioLinker's most recent funding round was Seed on October 6, 2026.
Who are the main investors in BioLinker?
Key investors in BioLinker include Axcell Aceleradora.
Will BioLinker IPO soon?
No public IPO plans have been announced for BioLinker.
How can I track BioLinker secondary market activity?
Caplight tracks bids, offers, and trades in BioLinker's shares on secondary markets.